Recursion Pharmaceuticals (RXRX): Navigating Q1 Setbacks with Strong Pipeline Momentum and Analyst Upside
Key Takeaways
- Recursion Pharmaceuticals reported Q1 2026 revenue of $6.47 million, missing estimates, with a net loss of $117.5 million but cash reserves of $665.2 million extending runway into early 2028.
- Clinical advancements include positive early data for REC-1245 (no dose-limiting toxicities) and REC-4881 (polyp reductions in familial adenomatous polyposis), alongside first dosing in REC-4539.
- Analyst consensus leans overweight with an average price target of $6.64, implying over 100% upside from recent levels around $3.05.
- Partnership milestones with Sanofi, Roche, and Genentech have delivered over $500 million in inflows, supporting a diversified pipeline.
- Stock trades near 52-week lows amid biotech sector volatility, with elevated short interest adding potential for sentiment shifts.
A Closer Look at RXRX's Current Market Position
I've been keeping a close eye on Recursion Pharmaceuticals (RXRX) as it trades near the bottom of its 52-week range. This reflects not just broader biotech sector pressures but also the company's recent financial results. The shares have swung with clinical updates and earnings releases, sitting well below where analysts see fair value. Trading volumes have picked up, showing real investor engagement, and the solid cash position offers some reassurance while R&D spending continues. From what I see, the sentiment here weighs excitement about AI-powered drug discovery against worries over revenue ramps and profitability—the classic high-risk, high-reward profile in TechBio.
Recent Developments Shaping RXRX's Trajectory
Recursion Pharmaceuticals (RXRX), a clinical-stage TechBio firm using AI to accelerate drug discovery, has faced downward pressure lately amid mixed Q1 2026 results and sector challenges. On May 6, 2026, they posted first-quarter revenue of $6.47 million, missing the $15.78 million consensus due to softer milestone payments than expected. The net loss improved slightly to $117.5 million, and cash, cash equivalents, and restricted cash stood at $665.2 million as of March 31, 2026—down from $753.9 million at the end of 2025, but enough to carry operations into early 2028 without new funding. Management stuck to their 2026 cash burn guidance under $390 million, building on last year's 35% expense cut that demonstrates real discipline.
This earnings miss sparked a more than 10% drop in the sessions after, as investors zeroed in on revenue timelines. That said, pipeline progress offered some offset. Early Phase 1 results for REC-1245, a degrader targeting RBM39 in solid tumors, revealed no dose-limiting toxicities across 16 patients, with dose-dependent pharmacokinetics that support further escalation. For REC-4881, the oral MEK inhibitor in familial adenomatous polyposis (FAP), Phase 2 data showed median polyp burden reductions of 43% at week 13 and 53% at week 25, paving the way for FDA talks on a registrational study. They also dosed the first patient in the Phase 1 trial of REC-4539 for cerebral cavernous malformation.
Partnerships added to the positive side: Recursion hit a fifth milestone with Sanofi ($4 million) on a first-in-class oncology program, contributing to over $500 million in total inflows and more than 10 deliverables from deals with Sanofi (immunology/oncology), Roche, and Genentech (biology maps from massive iPSC-derived cell datasets). In April, a board change was noted, with founder Chris Gibson wrapping up his term in June 2026 but staying on as an advisor—continuity under CEO Najat Khan.
Analysts had varied takes: Needham stuck with Buy and an $8 target (May 7), Morgan Stanley lifted to $5.50 from $5 (Equal-Weight, May 14), Bank of America went Hold (May 13), and JPMorgan trimmed to $10 from $11 (Overweight, late April). The consensus holds Overweight (3 Buy, 5 Hold from 8 analysts), with an average target of $6.64 (high $10, low $3), pointing to significant upside. The stock mirrored this back-and-forth, sliding about 20% from early May peaks near $3.90 to around $3.05, close to 52-week lows, on average daily volume of 14 million and roughly 40% short interest. Growth biotech sensitivity to rates added to the downside, but clinical wins and partner backing kept buyers in the mix. I also checked this using Tickeron’s AI Screener to gauge how RXRX stacks up against industry peers.
Exploring Tickeron's Trending AI Robots
One tool I find useful in my analysis is Tickeron’s Trending AI Robots page. It curates over 25 top performers from a library of 351 AI trading bots designed for copy trading in stocks, ETFs, and crypto. These adapt to market shifts with strategies like real-time signal agents (no minimum balance needed), virtual agents for risk management and custom portfolios, and brokerage agents via Tickeron accounts. They run on short intervals—60-minute, 15-minute, or 5-minute charts—for different volatility setups. While results differ by bot, the trending ones stand out for recent strength in fast markets, including biotech like RXRX. It's worth a look if you're aiming to streamline your trading approach.
Looking Ahead to 2026: What Matters Most for RXRX
As 2026 unfolds, Recursion's path hinges on de-risking its pipeline and proving its platform in a crowded TechBio field. Consensus sees full-year revenue at $66-82 million from Sanofi milestones (development candidates in immunology/oncology), Roche/Genentech (target validation via multi-modal biology maps), and internal efforts. EPS should land around -$0.93, with losses tied to R&D growth, but the sub-$390 million burn keeps cash into 2028.
I'm watching REC-4881's FAP registrational potential, REC-1245 expansion, and Phase 1 data from REC-4539/REC-3565 in oncology/neuroscience. Partnerships lower risks, with opt-ins possible on five programs. Broader trends like AI speeding trial enrollment (30-60% faster via ClinTech) and real-world data from the Citeline partnership could help. On the flip side, clinical flops, regulatory snags for degraders, delayed milestones, or rivals like Exscientia pose threats. Upside could come from oncology/rare disease orphan status, efficiencies in Recursion OS 2.0, and biotech rebounds. Keep an eye on Q2 earnings in August 2026, milestone news, and short interest for turning points—this is important because it could signal broader sentiment shifts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
RXRX's Stochastic Oscillator ascending into overbought zone
The Stochastic Oscillator for RXRX moved into overbought territory on August 21, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RXRX broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RXRX's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 19, 2026. You may want to consider a long position or call options on RXRX as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for RXRX just turned positive on August 04, 2026. Looking at past instances where RXRX's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
RXRX moved above its 50-day moving average on August 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for RXRX crossed bullishly above the 50-day moving average on August 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 123 cases where RXRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.051) is normal, around the industry mean (20.145). P/E Ratio (0.000) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (32.895) is also within normal values, averaging (444.692).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement